Results 111 to 120 of about 543,415 (269)

Discovery of SKP2‐Recruiting PROTACs for Target Protein Degradation

Advanced Science, EarlyView.
Based on the SKP2‐targeting ligand SL1, we designed non‐covalent PROTACs by linking it with the BRD4 inhibitor JQ1 and the AR antagonist AL through a linker. These PROTACs successfully induced the ubiquitination of BRD4 and AR, followed by proteasome‐mediated degradation.
Guanjun Dong, Aima Huang, Ziqing Zhao, Bikai Lai, Xin Pan, Huiyu Yang, Xiaohan Xu, Tianwei Wang, Fangchen Zhao, Zhimin Zhang, Yongbo Xue, Guanjun Deng, Wenbin Deng, Jianwei Chen   +13 more
wiley   +1 more source

Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2

Haematologica, 2018
Constance Baer, Verena Muehlbacher, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +4 more
doaj   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity

Blood Cancer Journal
Isolde Summerer, Wencke Walter, Manja Meggendorfer, Torsten Haferlach, Frank Dicker, Stephan Hutter, Niroshan Nadarajah, Anna Stengel, Constanze Kuehn, Wolfgang Kern, John M. Bennett, Claudia Haferlach, Christian Pohlkamp   +12 more
doaj   +1 more source

Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease

Haematologica, 2019
Anna Stengel, Sabine Jeromin, Torsten Haferlach, Manja Meggendorfer, Wolfgang Kern, Claudia Haferlach   +5 more
doaj   +1 more source

P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA

HemaSphere, 2022
J. Senapati, H. Kantarjian, N. Short, M. Konopleva, F. Ravandi, N. Jain, P. A. Thompson, N. Pemmaraju, W. G. Wierda, G. Borthakur, T. M. Kadia, G. Garcia-Manero, M. Yilmaz, J. Thankachan, M. Zhao, C. Loiselle, M. T. Talley, M. I. Kwari, R. S. Garris, E. J. Jabbour   +19 more
doaj   +1 more source

TTNPB Promotes Human Pluripotent Stem Cell‐to‐Neural Stem Cell Transition via Modulation of Chromatin Accessibility and the S‐(5′‐adenosyl)‐L‐homocysteine/Choline Metabolic Network

Advanced Science, EarlyView.
A retinoic acid receptor agonist, TTNPB, drives the efficient generation of advanced neural stem cells (ANSCs) from human pluripotent stem cells. TTNPB‐centered chromatin remodeling and metabolic reprogramming, promote neuroectoderm commitment. The resulting cells show robust neural potential and functional efficacy in a rat depression model.
Ruilin Du, Yudi Ren, Qiaoqiao Meng, Peng Wei, Ruyu Zhu, Junjie Bao, Ye Yang, Shuo Yan, Chaorong Yue, Xueying Zhu, Shuo Cao, Chunxia Hao, Wei Sun, Yongli Song, Xihe Li, Zhimin Wu, Siqin Bao, Yanglin Chen   +17 more
wiley   +1 more source

Two ways to complex karyotype in MDS—the role of del(5q) and TP53

Blood Cancer Journal
Sandra Huber, Stephan Hutter, Constance Baer, Manja Meggendorfer, Gregor Hoermann, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach   +7 more
doaj   +1 more source

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS

HemaSphere, 2022
S. P. Desikan, G. Montalban-Bravo, M. Ohanian, N. Daver, T. Kadia, S. Venugopal, K. Chien, H. Kantarjian, G. Garcia-Manero   +8 more
doaj   +1 more source

Invasive Fusariosis Among Patients with Acute Leukemia: A 12-Year Single-Center Experience in a Middle-Income Country. [PDF]

Mycopathologia
de Luca Ito RK, Bonazzi Pontes PR, Kono Magri ASG, Ibrahim KY, Encinas Sejas ON, Katayose Goto JT, Pereira J, de Souza Carvalho Melhem M, Magri MMC, Abdala E.   +9 more
europepmc   +1 more source